Novo Nordisk out-licenses US hormone replacement therapyportfolio to Pharmacia & Upjohn "We are pleased to announce this agreement with Pharmacia & Upjohn, a well-established and experienced company in this therapy field. This multi-year agreement is a cornerstone in our efforts to...

New brand identities for the Novo group of companies The new brands were developed with the aim to position not only the uniqueness of each company but also the common family identity. To emphasise the family identity the three companies will all...

Status re Novo Nordisk's holding of its own shares The company's holding of its own shares at the end of 1999 was 4,514,059 B shares, corresponding to 5.98% of the total capital stock as of the end of 1999. A total of 523,000 B shares were...